Authors: Kelsen, D

Citation: D. Kelsen, Preoperative chemoradiotherapy for esophageal cancer, J CL ONCOL, 19(2), 2001, pp. 283-285

Authors: Schwartz, GK Ilson, D Saltz, L O'Reilly, E Tong, W Maslak, P Werner, J Perkins, P Stoltz, M Kelsen, D

Citation: Gk. Schwartz et al., Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma, J CL ONCOL, 19(7), 2000, pp. 1985-1992

Authors: Kelsen, D Pajak, T Ginsberg, R

Citation: D. Kelsen et al., Treatment of esophageal cancer - Reply, N ENG J MED, 340(21), 1999, pp. 1686-1687

Authors: Saltz, LB Spriggs, D Schaaf, LJ Schwartz, GK Ilson, D Kemeny, N Kanowitz, J Steger, C Eng, M Albanese, P Semple, D Hanover, CK Elfring, GL Miller, LL Kelsen, D

Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865

Authors: Costa, F Schwartz, G Kelsen, D

Citation: F. Costa et al., Adjuvant chemotherapy in gastric adenocarcinomas, CANC TREAT, 98, 1998, pp. 41-63